

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM503013

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	INTELLECTUAL PROPERTY SECURITY AGREEMENT		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Zavante Therapeutics, Inc.		12/20/2018	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Hercules Capital, Inc.		
Street Address:	400 Hamilton Avenue, Suite 310		
City:	Palo Alto		
State/Country:	CALIFORNIA		
Postal Code:	94301		
Entity Type:	Corporation: MARYLAND		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	4814069	ZAVANTE THERAPEUTICS, INC.	
Registration Number:	4697125	ZAVANTE	
CORRESPONDENCE DATA			
Fax Number:	7147558290		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	714-540-1235		
Email:	ipdocket@lw.com		
Correspondent Name:	Latham & Watkins LLP		
Address Line 1:	650 Town Center Drive, Suite 2000		
Address Line 4:	Costa Mesa, CALIFORNIA 92626		
ATTORNEY DOCKET NUMBER:	054809-0039		
NAME OF SUBMITTER:	Anna T Kwan		
SIGNATURE:	/atk/		
DATE SIGNED:	12/20/2018		
Total Attachments: 39			
source=Nabriva - Intellectual Property Security Agreement Executed_104413900_7_0#page1.tif			
source=Nabriva - Intellectual Property Security Agreement Executed_104413900_7_0#page2.tif			
source=Nabriva - Intellectual Property Security Agreement Executed_104413900_7_0#page3.tif			
source=Nabriva - Intellectual Property Security Agreement Executed_104413900_7_0#page4.tif			

OP \$65.00 4814069

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (“Agreement”) dated as of December 20, 2018, is made by Nabriva Therapeutics Public Limited Company, a public limited company incorporated in Ireland under registration number 599588 and having its registered office at 25-28 North Wall Quay, Dublin 1, Ireland (“Parent”), Nabriva Therapeutics Ireland Designated Activity Company, a designated activity company incorporated in Ireland under registration number 612454 and having its registered office at Suite 510, Regus Dublin Airport, Skybridge House, Dublin Airport, Swords, County Dublin, Ireland (“Nabriva Ireland”), Nabriva Therapeutics GmbH, a limited liability company (*Gesellschaft mit beschränkter Haftung*) incorporated under the laws of the Republic of Austria, having its seat in Vienna and its registered address at Leberstraße 20, 1110 Vienna, and registered with the companies’ register (*Firmenbuch*) of the commercial court of Vienna (*Handelsgericht Wien*) under registration number FN 269261 y (“Nabriva Austria”), Nabriva Therapeutics US, Inc., a Delaware corporation (“Nabriva US”), Zavante Therapeutics, Inc., a Delaware corporation (“Zavante”), and each domestic Subsidiary signatory hereto (individually and collectively, the “Grantor”), in favor of Hercules Capital, Inc. (“Agent”) in its capacity as administrative agent and collateral agent for the Lenders (as defined below).

RECITALS

A. Grantor has entered into a Loan and Security Agreement with certain financial institutions party thereto (the “Lenders”) and Agent, in its capacity as administrative agent and collateral agent for itself and the Lenders, dated as of the date hereof (as amended, restated, or otherwise modified from time to time, the “Loan Agreement”). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral, but with respect Nabriva Austria only to the extent the Collateral is not governed by Austrian law and with respect to Parent and Nabriva Ireland only to the extent the Collateral is not governed by Irish law.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property, but (a) with respect to Parent and Nabriva Ireland only to the extent not governed by Irish law, and (b) with respect to Nabriva Austria only to the extent not governed by Austrian law (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing, the Intellectual Property Collateral does not include (i) any “intent to use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, provided, that upon submission and acceptance by the United States Patent and Trademark Office of an amendment to allege use of an intent-to-use trademark application pursuant to 15 U.S.C. Section 1060(a) (or any successor provision) such intent-to-use application shall constitute Intellectual Property Collateral, (ii) any interest of any Loan Party as a lessee under an Equipment lease if such Loan Party is prohibited by the terms of such lease from granting a security interest in such lease or under which such an assignment or Lien would cause a default to occur under such lease; provided, however, that upon termination or cessation of such prohibition, such interest shall immediately become Collateral without any action by any Loan Party, Agent or Lenders or (iii) any FFG Restricted Assets (as defined in the Loan Agreement).

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Agent.

Grantor hereby authorizes Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall

constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Agent's successors and assigns.

6. Austrian Capital Maintenance. All obligations and liabilities of Nabriva Austria as Grantor under this Agreement or any other Loan Document shall be limited in accordance with subsection 12.11 (*General Limitations – Austrian Guarantor*) of the Loan Agreement and subsection 12.11 (*General Limitations – Austrian Guarantor*) of the Loan Agreement shall apply to this Agreement as if set out herein in full.

7. Governing Law. This Agreement has been negotiated and delivered to Agent in the State of New York, and shall have been accepted by Agent in the State of New York. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

[Signature page follows.]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Nabriva Therapeutics Public Limited Company

GIVEN under the **COMMON SEAL** of

NABRIVA THERAPEUTICS PUBLIC LIMITED COMPANY

and **DELIVERED** as a **DEED**:



Gary Sender
Authorised Signatory



Nabriva Therapeutics Ireland Designated Activity Company

SIGNED AND DELIVERED as a Deed

for and on behalf of

NABRIVA THERAPEUTICS IRELAND DESIGNATED ACTIVITY COMPANY



by its lawfully appointed attorney

GARY SENDER




Signature of Attorney

in the presence of:


Signature of Witness
Occupation of Witness

1000 Continental Drive, #400
Address of Witness King of Prussia, PA 19406

NABRIVA THERAPEUTICS GMBH

By: 
Name: Gary Sender
Title: Authorised Signatory

NABRIVA THERAPEUTICS US, INC.

By: 
Name: Gary Sender
Title: Treasurer

ZAVANTE THERAPEUTICS, INC.

By: 
Name: Gary Sender
Title: Treasurer

AGENT:

HERCULES CAPITAL, INC., a Maryland
corporation

By: *Melanie Grace*

Name: Melanie Grace

Title: General Counsel

[Signature Page to Intellectual Property Security Agreement (Hercules/Nabriva)]

TRADEMARK
REEL: 006561 FRAME: 0362

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

See attachment.

No. 1: N 31092 (BC-3205 generically and phenyl Pleuromutilins)

Country	Filing Date	Application number	Grant date	Patent number	Status
GB	30.07.1999	9918037.4			Abandoned
BR	28.07.2000	PI0017527-7	19.08.2017	PI0017527-7	Granted
BR	28.07.2000	PI0017568-4			Abandoned
BR	28.07.2000	PI0012880-5			Abandoned
EP	28.07.2000	05022003.7	01.12.2010	1 666 466	Granted
BE	28.07.2000	05022003.7	01.12.2010	1 666 466	Granted
CH	28.07.2000	05022003.7	01.12.2010	1 666 466	Granted
DE	28.07.2000	05022003.7	01.12.2010	600 45 321.9-08	Granted
ES	28.07.2000	05022003.7	01.12.2010	1 666 466	Granted
FR	28.07.2000	05022003.7	01.12.2010	1 666 466	Granted
GB	28.07.2000	05022003.7	01.12.2010	1 666 466	Granted
IT	28.07.2000	05022003.7	01.12.2010	502011901918517	Granted
NL	28.07.2000	05022003.7	01.12.2010	1 666 466	Granted
TW	19.07.2000	89114436	21.05.2007	I281468	Granted
WO	28.07.2000	PCT/EP00/07309			Terminated
EP	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
AT	28.07.2000	00956343.8	08.03.2006	E 319686	Granted
BE	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
CH	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
CY	28.07.2000	00956343.8	08.03.2006	1 198 454	Abandoned
DE	28.07.2000	00956343.8	08.03.2006	600 26 540.4-08	Granted
DK	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
ES	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
FI	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
FR	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
GB	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
GR	28.07.2000	00956343.8	08.03.2006	3057410	Granted
IE	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
IT	28.07.2000	00956343.8	08.03.2006	502006901406191	Granted
NL	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
PT	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted

Country	Filing Date	Application number	Grant date	Patent number	Status
SE	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
SI	28.07.2000	00956343.8	08.03.2006	1 198 454	Granted
CA	28.07.2000	2,380,980	14.04.2009	2,380,980	Granted
CN	28.07.2000	00810838.2	29.12.2004	ZL 00810838.2	Granted
CN	28.07.2000	200410089793.5			Abandoned
HU	28.07.2000	P0202071	7.12.2013	229 483	Granted
IN	28.07.2000	IN/PCT/2002/0096/CHE	05.09.2007	209549	Granted
IL	28.07.2000	147072	21.12.2007	147072	Granted
JP	28.07.2000	2001-514299	01.04.2011	4711580	Granted
JP	28.07.2000	2010-204065	28.02.2014	5485838	Granted
KR	28.07.2000	10-2002-7001275	05.01.2009	10-0878074	Granted
KR	28.07.2000	10-2007-7017673	05.01.2009	10-0878075	Granted
NO	28.07.2000	20020383	23.10.2006	322562	Granted
PL	28.07.2000	P 352940	28.12.2010	205609	Granted
PL	28.07.2000	P-386375/DP			Abandoned
US	28.07.2000	10/048,438	31.08.2004	6,784,193	Granted
US	28.07.2000	10/867,232	19.05.2009	7,534,814	Granted
HK	28.07.2000	02106950.3	22.12.2006	HK1047087	Granted
HK	28.07.2000	05108320.9			Abandoned
HK	28.07.2000	06111238.3	11.03.2011	HK1090636	Granted

Expiration dates No. 1:

TW I281468:	July 19, 2020
US 6,784,193:	July 28, 2020 + 77 days
US 7,534,814:	July 28, 2020 + 593 days
All other countries:	July 28, 2020

No. 2: N 31504 (Cycloalkyl Pleuromutilins basic - BC-3781 generic compound case)

Country	Filing Date	Application number	Grant date	Patent number	Status
GB	11.07.2000	0017031.6			Abandoned
EP	09.07.2001	01954024.4	17.09.2008	1 305 282	Granted
AT	09.07.2001	01954024.4	17.09.2008	E 408596	Granted
CH	09.07.2001	01954024.4	17.09.2008	1 305 282	Granted
DE	09.07.2001	01954024.4	17.09.2008	601 35 848.1-08	Granted
ES	09.07.2001	01954024.4	17.09.2008	1 305 282	Granted
FR	09.07.2001	01954024.4	17.09.2008	1 305 282	Granted
GB	09.07.2001	01954024.4	17.09.2008	1 305 282	Granted
IE	09.07.2001	01954024.4	17.09.2008	1 305 282	Granted
IT	09.07.2001	01954024.4	17.09.2008	502008901686725	Granted
NL	09.07.2001	01954024.4	17.09.2008	1 305 282	Granted
SI	09.07.2001	01954024.4	17.09.2008	1 305 282	Granted
TW	09.07.2001	90116687	01.07.2009	I311552	Granted
WO	09.07.2001	PCT/EP01/07875			Terminated
BR	09.07.2001	PI0112452-8	01.06.2015	PI0112452-8	Granted
CA	09.07.2001	2,412,932	04.01.2011	2,412,932	Granted
CN	09.07.2001	01812541.7	04.04.2007	ZL01812541.7	Granted
HU	09.07.2001	P0301478	11.12.2013	229 510	Granted
IN	09.07.2001	8/CHENP/2003	26.11.2007	212191	Granted
IL	09.07.2001	153839	30.06.2012	153839	Granted
JP	09.07.2001	2002-509081	06.02.2009	4255282	Granted
JP	09.07.2001	2008-300463	11.01.2013	5173763	Granted
KR	09.07.2001	10-2003-7000353	07.04.2009	10-0893426	Granted
NO	09.07.2001	20030100	23.08.2010	329091	Granted
PL	09.07.2001	P 358674	25.02.2011	209305	Granted
US	09.07.2001)	10/339,611	22.06.2004	US 6,753,445	Granted
HK	09.07.2001	03104840.1	22.05.2009	HK1052683	Granted

Expiration Dates No. 2:

All countries July 9, 2021

No. 3: N 31546 (BC-3205 stereoisomer and pyrrolidine Pleuromutilins)

Country	Filing Date	Application number	Grant date	Patent number	Status
GB	13.09.2000	0022440.2			Abandoned
GB	13.09.2000	0022439.4			Abandoned
GB	09.10.2000	0024674.4			Abandoned
US	11.09.2001	12/384,580			Abandoned
TW	11.09.2001	90122488	01.03.2009	I306852	Granted
WO	11.09.2001	PCT/EP01/10502			Terminated
EP	11.09.2001	01972046.5	21.04.2004	1 320 525	Granted
AT	11.09.2001	01972046.5	21.04.2004	E 264843	Granted
BE	11.09.2001	01972046.5	21.04.2004	1 320 525	Granted
CH	11.09.2001	01972046.5	21.04.2004	1 320 525	Granted
DE	11.09.2001	01972046.5	21.04.2004	601 02 936	Granted
ES	11.09.2001	01972046.5	21.04.2004	2220809	Granted
FR	11.09.2001	01972046.5	21.04.2004	1 320 525	Granted
GB	11.09.2001	01972046.5	21.04.2004	1 320 525	Granted
GR	11.09.2001	20040402481	21.04.2004	3049977	Granted
IT	11.09.2001	01972046.5	21.04.2004	502004901230870	Granted
NL	11.09.2001	01972046.5	21.04.2004	1 320 525	Granted
PT	11.09.2001	01972046.5	21.04.2004	1 320 525	Granted
SE	11.09.2001	01972046.5	21.04.2004	1 320 525	Granted
BR	11.09.2001	PI0113837-5			Pending
BR	11.09.2001	PI0117346-4			Abandoned
CA	11.09.2001	2,418,538	22.12.2009	2,418,538	Granted
CN	11.09.2001	01815576.6	06.12.2006	ZL01815576.6	Granted
JP	11.09.2001	2002-526833	16.11.2012	5134181	Granted
US	11.09.2001	10/363,840	30.01.2007	7,169,804	Granted
US	11.09.2001	11/652,812	04.08.2009	7,569,587	Granted
HK	11.09.2001	05111385.5	09.03.2007	HK1079506	Granted

Expiration dates No. 3:

US 7,169,804: September 11, 2021+ 185 days
 US 7,569,587: September 11, 2021+ 31 days
 All other countries: September 11, 2021

No. 4: N 32413 (Pleuromutilin use patent for tuberculosis treatment)

Country	Filing Date	Application number	Grant date	Patent number	Status
GB	28.03.2002	0207495.3			Abandoned
GB	24.07.2002	0217149.4			Abandoned
GB	25.07.2002	0217305.2			Abandoned
EP	27.03.2003	07012020.9	28.07.2010	1 875 903	Granted
BE	27.03.2003	07012020.9	28.07.2010	1 875 903	Granted
CH	27.03.2003	07012020.9	28.07.2010	1 875 903	Granted
DE	27.03.2003	07012020.9	28.07.2010	603 33 605.1-08	Granted
ES	27.03.2003	07012020.9	28.07.2010	1 875 903	Granted
FR	27.03.2003	07012020.9	28.07.2010	1 875 903	Granted
GB	27.03.2003	07012020.9	28.07.2010	1 875 903	Granted
IE	27.03.2003	07012020.9	28.07.2010	1 875 903	Granted
IT	27.03.2003	07012020.9	28.07.2010	502010901884094	Granted
NL	27.03.2003	07012020.9	28.07.2010	1 875 903	Granted
SI	27.03.2003	07012020.9	28.07.2010	1 875 903	Granted
EP	27.03.2003	03714893.9			Abandoned
TW	27.03.2003	092106937	21.10.2010	1331916	Granted
WO	27.03.2003	PCT/EP03/03215			Terminated
BR	27.03.2003	PI 0308813-8			Abandoned
CN	27.03.2003	03807361.7			Abandoned
IN	27.03.2003	2130/CHENP/2004	16.02.2009	229282	Granted
IN	27.03.2003	4984/CHENP/2007			Abandoned
JP	27.03.2003	2003-579798	25.03.2011	4708708	Granted
PL	27.03.2003	P 371268	20.12.2012	214755	Granted
US	27.03.2003	10/509,502			Abandoned
US	27.03.2003	11/818,094	03.01.2012	8,088,823	Granted
US	27.03.2003	13/317,666			Abandoned
HK	27.03.2003	05104910.4			Abandoned
ID	27.03.2003	W-00200402073			Abandoned
MX	27.03.2003	PA/a/2004/009454			Abandoned
RU	27.03.2003	2004 131 686			Abandoned
SG	27.03.2003	200405180-1	31.10.2007	106737	Granted
ZA	27.03.2003	2004/7216	31.08.2005	2004/7216	Abandoned
TH	26.03.2003	0301001132			Abandoned

Expiration dates No. 4:

US 8,088,823:

March 27, 2023 + 1123 days

All other countries:

March 27, 2023

TRADEMARK**REEL: 006561 FRAME: 0369**

No. 5: N 32439 (Pleuromutilin use patent for Helicobacter treatment)

Country	Filing Date	Application number	Grant date	Patent number	Status
GB	23.04.2002	0209262.5			Abandoned
EP	22.04.2003	03732288.0	08.09.2010	1 501 495	Granted
BE	22.04.2003	03732288.0	08.09.2010	1 501 495	Granted
CH	22.04.2003	03732288.0	08.09.2010	1 501 495	Granted
DE	22.04.2003	03732288.0	08.09.2010	603 34 094.6-08	Granted
ES	22.04.2003	03732288.0	08.09.2010	1 501 495	Granted
FR	22.04.2003	03732288.0	08.09.2010	1 501 495	Granted
GB	22.04.2003	03732288.0	08.09.2010	1 501 495	Granted
IT	22.04.2003	03732288.0	08.09.2010	502010901895522	Granted
NL	22.04.2003	03732288.0	08.09.2010	1 501 495	Granted
SI	22.04.2003	03732288.0	08.09.2010	1 501 495	Granted
TW	21.04.2003	092109216			Abandoned
WO	22.04.2003	PCT/EP03/04173			Terminated
JP	22.04.2003	2003-587374			Abandoned
US	22.04.2003	10/510,532	07.09.2010	7,790,749	Granted
HK	22.04.2003	05105973.5	25.02.2011	HK1073250	Granted

Expiration dates No. 5:

US 7,790,749: April 22, 2023 + 921 days
 All other countries: April 22, 2023

No. 6: N 32577 (Hydroxypiperidine Pleuromutilins)

Country	Filing Date	Application number	Grant date	Patent number	Status
GB	24.07.2002	0217149.4			Abandoned
GB	25.07.2002	0217305.2			Abandoned
EP	23.07.2003	03771076.1	31.10.2007	1 534 678	Granted
AT	23.07.2003	03771076.1	31.10.2007	E 377001	Granted
CH	23.07.2003	03771076.1	31.10.2007	1 534 678	Granted
DE	23.07.2003	03771076.1	31.10.2007	603 17 208.3-08	Granted
ES	23.07.2003	03771076.1	31.10.2007	1 534 678	Granted
FR	23.07.2003	03771076.1	31.10.2007	1 534 678	Granted
GB	23.07.2003	03771076.1	31.10.2007	1 534 678	Granted
HU	23.07.2003	03771076.1	31.10.2007	E003227	Granted
IE	23.07.2003	03771076.1	31.10.2007	1 534 678	Granted
IT	23.07.2003	03771076.1	31.10.2007	502008901592117	Granted
NL	23.07.2003	03771076.1	31.10.2007	1 534 678	Granted
SI	23.07.2003	03771076.1	31.10.2007	1 534 678	Granted
WO	23.07.2003	PCT/EP2003/008059			Terminated
BR	23.07.2003	PI0312882-2			Pending
CN	23.07.2003	03817643.2	19.12.2007	ZL 03 8 17643.2	Granted
IN	23.07.2003	3123/CHENP/2004	05.02.2009	228626	Granted
JP	23.07.2003	2004-523769	22.10.2010	4611020	Granted
PL	23.07.2003	P 373460			Abandoned
US	23.07.2003	10/521,926	03.11.2009	7,612,103	Granted
HK	23.07.2003	05110838.0	11.04.2008	HK1079191	Granted

Expiration dates No. 6:

US 7,612,103: July 23, 2023 + 612 days
 All other countries: July 23, 2023

No. 7: N 34326 (Specific Pleuromutilin salt case including BC-3205 inter alia for acne treatment)

Country	Filing Date	Application number	Grant date	Patent number	Status
GB	27.06.2005	0513058.8			Abandoned
EP	14.06.2006	502008901592117.2	10.08.2011	1 896 405	Granted
DE	14.06.2006	06752578.2	10.08.2011	60 2006 023 691.3	Granted
FR	14.06.2006	06752578.2	10.08.2011	1 896 405	Granted
GB	14.06.2006	06752578.2	10.08.2011	1 896 405	Granted
JP	14.06.2006	2008-518553			Abandoned
US	14.06.2006	11/993,813			Abandoned
TW	22.06.2006	095122515			Abandoned
WO	14.06.2006	PCT/AT2006/000242			Terminated

Expiration dates No. 7:

All countries June 14, 2026

No. 8: N 34330 (Hydroxy- or acyloxyamino-cycloalkyl Pleuromutilins)

Country	Filing Date	Application number	Grant date	Patent number	Status
GB	27.06.2005	0513060.4			Abandoned
GB	03.08.2005	0515997.5			Abandoned
US	26.06.2006	11/814,672	07.09.2010	7,790,767	Granted
EP	26.06.2006	06741055.5	17.09.2014	1 896 404	Granted
DE	26.06.2006	06741055.5	17.09.2014	60 2006 043 069.8	Granted
FR	26.06.2006	06741055.5	17.09.2014	1 896 404	Granted
GB	26.06.2006	06741055.5	17.09.2014	1 896 404	Granted
JP	26.06.2006	2008-518554	27.09.2013	5373393	Granted
EP	26.06.2006	10009685.8	25.05.2016	2 298 733	Granted
DE	26.06.2006	10009685.8	25.05.2016	60 2006 049 215.4	Granted
FR	26.06.2006	10009685.8	25.05.2016	2 298 733	Granted
GB	26.06.2006	10009685.8	25.05.2016	2 298 733	Granted
WO	26.06.2006	PCT/AT2006/000260			Terminated
TW	26.06.2006	095122957			Abandoned

Expiration dates No. 8:

US 7,790,767: June 26, 2026 + 503 days
 All other countries: June 26, 2026

No. 9: N 34406 ((Di)alkyl-, heterocyclyl-, cyclyolalkyl-amino- or heterocyc-N-yl-cycloylkalkyl Pleuromutilins)

Country	Filing Date	Application number	Grant date	Patent number	Status
GB	03.08.2005	0515995.9			Abandoned
EP	26.07.2006	06760805.9	02.07.2014	1 910 282	Granted
DE	26.07.2006	06760805.9	02.07.2014	60 2006 042 140.0	Granted
FR	26.07.2006	06760805.9	02.07.2014	1 910 282	Granted
GB	26.07.2006	06760805.9	02.07.2014	1 910 282	Granted
JP	26.07.2006	2008-524308	27.09.2013	5372505	Granted
US	26.07.2006	11/997,637	01.01.2013	8,343,972	Granted
EP	26.07.2006	10009686.6			Abandoned
TW	02.08.2006	095128307	11.11.2013	1414511	Granted
WO	26.07.2006	PCT/AT2006/000318			Terminated

Expiration dates No. 9:

TW 095128307: August 2, 2026
 All other countries: July 26, 2026

No. 10: N 34744 (BC-7013 and alkylamino- and alkyl-imino phenyl-sulfanyl-acetyl Mutilins)

Country	Filing Date	Application number	Grant date	Patent number	Status
EP	16.01.2006	06000827.3			Abandoned
WO	11.01.2007	PCT/AT2007/000009			Terminated
TW	12.01.2007	96101295	01.03.2014	I428316	Granted
EP	11.01.2007	07700066.9	23.03.2011	1 838 665	Granted
CH	11.01.2007	07700066.9	23.03.2011	1 838 665	Granted
DE	11.01.2007	07700066.9	23.03.2011	60 2007 013 306.8-08	Granted
DK	11.01.2007	07700066.9	23.03.2011	1 838 665	Granted
ES	11.01.2007	07700066.9	23.03.2011	1 838 665	Granted
FR	11.01.2007	07700066.9	23.03.2011	1 838 665	Granted
GB	11.01.2007	07700066.9	23.03.2011	1 838 665	Granted
IT	11.01.2007	07700066.9	23.03.2011	502011901956373	Granted
NL	11.01.2007	07700066.9	23.03.2011	1 838 665	Granted
PL	11.01.2007	07700066.9	23.03.2011	1 838 665	Granted
US	11.01.2007	11/814,673	19.10.2010	7,816,389	Granted
BR	11.01.2007	PI0707117-5			Pending
CA	11.01.2007	2,635,950	30.08.2016	2,635,950	Granted
CN	11.01.2007	200780002479.0	24.09.2014	ZL200780002479.0	Granted
EA	11.01.2007	200870171	30.04.2014	019579	Granted
IL	11.01.2007	192756	30.01.2016	192756	Granted
IN	11.01.2007	5764/DELNP/2008	12.02.2015	265189	Granted
JP	11.01.2007	2008-549710	07.03.2014	5489467	Granted
JP	11.01.2007	2013-008588			Abandoned
KR	11.01.2007	10-2008-7019893	20.08.2014	10-1434683	Granted
NO	11.01.2007	20083409			Granted
HK	11.01.2007	09104021.6	30.01.2015	HK1125624	Granted
EP	11.01.2007	10009549.6	26.07.2017	2 266 955	Granted
CH	11.01.2007	10009549.6	26.07.2017	2 266 955	Granted
DE	11.01.2007	10009549.6	26.07.2017	2 266 955	Granted
FR	11.01.2007	10009549.6	26.07.2017	2 266 955	Granted
GB	11.01.2007	10009549.6	26.07.2017	2 266 955	Granted
IE	11.01.2007	10009549.6	26.07.2017	2 266 955	Granted



Country	Filing Date	Application number	Grant date	Patent number	Status
HK	11.01.2007	08100510.3			Abandoned

Expiration dates No. 10:

TW 96101295: January 12, 2027
All other countries: January 11, 2027

No. 11: BC-3205 preparation process including crystalline HCl salt

Country	Filing Date	Application number	Grant date	Patent number	Status
EP	05.10.2006	06121852.5			Abandoned
WO	03.10.2007	PCT/AT2007/000468			Terminated
TW	03.10.2007	96137112	01.04.2014	I432416	Granted
HK	08.10.2008	08111123.9			Abandoned
EP	03.10.2007	07815135.4	07.09.2011	2 069 301	Granted
CH	03.10.2007	07815135.4	07.09.2011	2 069 301	Granted
DE	03.10.2007	07815135.4	07.09.2011	60 2007 017 048.6	Granted
ES	03.10.2007	07815135.4	07.09.2011	2 069 301	Granted
FR	03.10.2007	07815135.4	07.09.2011	2 069 301	Granted
GB	03.10.2007	07815135.4	07.09.2011	2 069 301	Granted
IT	03.10.2007	07815135.4	07.09.2011	502011902002580	Granted
AU	03.10.2007	2007304867	23.05.2013	2007304867	Granted
BR	03.10.2007	PI0719205-3			Pending
CA	03.10.2007	2,665,347	14.02.2017	2,665,347	Granted
CN	03.10.2007	200780045162.5	24.12.2014	ZL200780045162.5	Granted
HR	03.10.2007	P20090192A	19.04.2016	P20090192	Granted
IL	03.10.2007	197970	31.12.2014	197970	Granted
IN	03.10.2007	633/MUMNP/2009	17.03.2016	272110	Granted
JP	03.10.2007	2009-530732	13.06.2014	5557530	Granted
KR	03.10.2007	10-2009-7008971	09.12.2015	10-1577675	Granted
MX	03.10.2007	MX/a/2009/003681	30.11.2011	292926	Granted
MY	03.10.2007	PI20091363	15.08.2012	MY-146357-A	Granted
NO	03.10.2007	20091261	12.02.2018	341868	Granted
NZ	03.10.2007	576034	07.11.2011	576034	Granted
PH	03.10.2007	1-2009-500639	02.09.2013	1-2009-500639	Granted
RU	03.10.2007	2009116945	10.04.2014	2512591	Granted
SG	03.10.2007	200902174-2	15.08.2011	151500	Granted
UA	03.10.2007	200904312	12.12.2011	96775	Granted
US	03.10.2007	12/444,330	18.12.2012	8,334,389	Granted
US	03.10.2007	13/662,063	07.01.2014	8,624,033	Granted
ZA	03.10.2007	2009/02159	30.06.2010	2009/02159	Granted
HK	03.10.2007	08111123.9			Abandoned

Country	Filing Date	Application number	Grant date	Patent number	Status
HK	03.10.2007	10104886.7	30.10.2015	HK1139135	Granted
EP	03.10.2007	10009550.4			Abandoned

Expiration dates No. 11:

US 8,334,389: October 3, 2027 + 382 days
All other countries: October 3, 2027

No. 12: N 003 (1- or 2-Hydroxy, alkoxy or cycloalkoxy-cyclohexyl-phenyl-sulfanyl-acetyl Mutilins, BC-3781 specific compound case)

Country	Filing Date	Application number	Grant date	Patent number	Status
EP	20.03.2007	07450053.9			Abandoned
US	25.07.2007	11/828,224			Abandoned
WO	19.03.2008	PCT/AT2008/000097			Terminated
TW	20.03.2008	97109871	01.09.2013	1406657	Granted
EP	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
AT	19.03.2008	08714294.9	07.09.2011	E 523486	Granted
BE	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
BG	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
CH	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
CY	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
CZ	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
DE	19.03.2008	08714294.9	07.09.2011	60 2008 009 558.4	Granted
DK	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
EE	19.03.2008	08714294.9	07.09.2011	E006097	Granted
ES	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
FI	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
FR	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
GB	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
GR	19.03.2008	08714294.9	07.09.2011	3076717	Granted
HR	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
HU	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
IE	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
IS	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
IT	19.03.2008	08714294.9	07.09.2011	502011902001733	Granted
LT	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
LU	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
LV	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
MC	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
MT	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
NL	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
NO	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted

TRADEMARK

REEL: 006561 FRAME: 0379

Country	Filing Date	Application number	Grant date	Patent number	Status
PL	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
PT	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
RO	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
SE	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
SI	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
SK	19.03.2008	08714294.9	07.09.2011	2 137 143	Granted
TR	19.03.2008	08714294.9	07.09.2011	TR 2011 11759 T4	Granted
AU	19.03.2008	2008229609	12.07.2012	2008229609	Granted
BR	19.03.2008	PI0809023-8			Pending
CA	19.03.2008	2,678,795	18.11.2014	2,678,795	Granted
CN	19.03.2008	200880007780.5	15.10.2014	ZL200880007780.5	Granted
CN	19.03.2008	201410406131.X	15.12.2017	ZL20140406131.X	Granted
DZ	19.03.2008	090517	09.06.2011	6691	Granted
EA	19.03.2008	200970868	30.10.2013	018707	Granted Annuities paid for AM, AZ, BY, KG, KZ, MD, RU, TM, TJ
EG	19.03.2008	PCT 1381/2009			Pending
ID	19.03.2008	W-00 2009 02596	17.01.2012	ID P0030053	Granted
IL	19.03.2008	200440	31.12.2013	200440	Granted
IN	19.03.2008	5818/DELNP/2009	21.06.2016	273636	Granted
JP	19.03.2008	2009-553863	21.02.2014	5479114	Granted
JP	19.03.2008	2014-024500	04.03.2016	5893651	Granted
KR	19.03.2008	10-2009-7018920	06.12.2014	10-1478593	Granted
LY	19.03.2008	3856/2009			Pending
MA	19.03.2008	32283	01.04.2010	31314	Granted
MY	19.03.2008	PI 20093722	14.06.2013	MY-148916-A	Granted
NZ	19.03.2008	579011	11.07.2011	579011	Granted
PH	19.03.2008	1-2009-501635	19.06.2015	1-2009-501635	Granted
SG	19.03.2008	200905497-4	30.03.2012	154816	Granted
SY	19.03.2008	8255			Pending
TN	19.03.2008	TN2009-0347	20.09.2011	21095	Granted
UA	19.03.2008	a 2009 10582	26.03.2012	97836	Granted
US	19.03.2008	12/531,839	06.12.2011	8,071,643	Granted
ZA	19.03.2008	2009/05590	27.10.2010	2009/05590	Granted

TRADEMARK
REEL: 006561 FRAME: 0380

Country	Filing Date	Application number	Grant date	Patent number	Status
HK	19.03.2008	10106270.6	30.12.2011	HK1140185	Granted
MX	27.08.2010	MX/a/2010/009451			Abandoned
EP	19.03.2008	11005863.3	28.12.2016	2 380 874	Granted
AT	19.03.2008	11005863.3	28.12.2016	E 857140	Granted
BE	19.03.2008	11005863.3	28.12.2016	2 380 874	Granted
CH	19.03.2008	11005863.3	28.12.2016	2 380 874	Granted
DE	19.03.2008	11005863.3	28.12.2016	60 2008 048 174.3	Granted
DK	19.03.2008	11005863.3	28.12.2016	2 380 874	Granted
ES	19.03.2008	11005863.3	28.12.2016	2 380 874	Granted
FR	19.03.2008	11005863.3	28.12.2016	2 380 874	Granted
GB	19.03.2008	11005863.3	28.12.2016	2 380 874	Granted
IE	19.03.2008	11005863.3	28.12.2016	2 380 874	Granted
IT	19.03.2008	11005863.3	28.12.2016	502017000033500	Granted
NL	19.03.2008	11005863.3	28.12.2016	2 380 874	Granted
PT	19.03.2008	11005863.3	28.12.2016	2 380 874	Granted
SE	19.03.2008	11005863.3	28.12.2016	2 380 874	Granted
HK	19.03.2008	12103189.1	08.12.2017	1162464	Granted
US	19.03.2008	13/252,732	10.04.2012	8,153,689	Granted
US	19.03.2008	13/438,160			Abandoned (Wilmerhale)
US	19.03.2008	14/283,734			Abandoned (Wilmerhale)
US	19.03.2008	15/480,756			Abandoned
US	19.03.2008	16/023,880			Pending

Expiration Dates No. 12:

TW 97109871:	March 20, 2028
US 8,071,643:	March 19, 2028 + 303 days
All other countries:	March 19, 2028

No. 13: N 004 (Acylated-3-aminomethyl-phenyl-sulfanyl- or -oxy-acetyl Mutilins)

Country	Filing Date	Application number	Grant date	Patent number	Status
EP	13.07.2007	07450124.8			Abandoned
TW	11.07.2008	97126507	21.01.2014	I423796	Granted
WO	11.07.2008	PCT/AT2008/000254			Terminated
BR	11.07.2008	PI0814231-9			Pending
CA	11.07.2008	2,693,015	18.10.2016	2,693,015	Granted
CN	11.07.2008	200880107284.7	20.08.2014	ZL200880107284.7	Granted
EA	11.07.2008	201070138	30.06.2014	019806	Granted
EP	11.07.2008	08772583.4	25.12.2013	2 173 707	Granted
CH	11.07.2008	08772583.4	25.12.2013	2 173 707	Granted
DE	11.07.2008	08772583.4	25.12.2013	60 2008 029 530.3	Granted
FR	11.07.2008	08772583.4	25.12.2013	2 173 707	Granted
GB	11.07.2008	08772583.4	25.12.2013	2 173 707	Granted
HK	11.07.2008	10105202.1	11.04.2014	HK1139127	Granted
IL	11.07.2008	202947	30.04.2015	202947	Granted
IN	11.07.2008	7719/CHENP/2009	27.12.2017	291097	Granted
JP	11.07.2008	2010-515316	12.09.2014	5613562	Granted
KR	11.07.2008	10-2010-7003165	20.08.2015	10-1547543	Granted
US	11.07.2008	12/668,769	08.05.2012	8,173,685	Granted

Expiration dates No. 13:

US 8,173,685: July 11, 2028 + 237 days
 All other countries: July 11, 2028

No. 14: N 005 (3-fold substituted phenyl- sulfanyl- or -oxy-acetyl Mutilins)

Country	Filing Date	Application number	Grant date	Patent number	Status
EP	13.07.2007	07450123.0			Abandoned
WO	11.07.2008	PCT/AT2008/000255			Terminated
TW	11.07.2008	97126506			Abandoned
EP	11.07.2008	08772584.2	25.12.2013	2 176 211	Granted
DE	11.07.2008	08772584.2	25.12.2013	60 2008 029 531.1	Granted
FR	11.07.2008	08772584.2	25.12.2013	2 176 211	Granted
GB	11.07.2008	08772584.2	25.12.2013	2 176 211	Granted
US	11.07.2008	12/668,690	23.06.2015	9,061,980	Granted

Expiration dates No. 14:

US 9,061,980: July 11, 2028 + 734 days
 All other countries: July 11, 2028

No. 15: N 007 (N-acylated amino-hydroxy-cyclohexyl-sulfanylacetyl Mutilins)

Country	Filing Date	Application number	Grant date	Patent number	Status
EP	02.09.2008	08450126.1			Abandoned
WO	17.08.2009	PCT/AT2009/000313			Terminated
TW	24.08.2009	98128395	21.02.2015	1473611	Granted
CA	17.08.2009	2,734,392	29.08.2017	2,734,392	Granted
CN	17.08.2009	200980134986.9			Abandoned
CN	17.08.2009	201510920380.5			Pending
EP	17.08.2009	09810900.2	20.04.2016	2 321 272	Granted
AT	17.08.2009	09810900.2	20.04.2016	E 792286	Granted
BE	17.08.2009	09810900.2	20.04.2016	2 321 272	Granted
CH	17.08.2009	09810900.2	20.04.2016	2 321 272	Granted
DE	17.08.2009	09810900.2	20.04.2016	60 2009 038 072.9	Granted
DK	17.08.2009	09810900.2	20.04.2016	2 321 272	Granted
ES	17.08.2009	09810900.2	20.04.2016	2 321 272	Granted
FR	17.08.2009	09810900.2	20.04.2016	2 321 272	Granted
GB	17.08.2009	09810900.2	20.04.2016	2 321 272	Granted
IE	17.08.2009	09810900.2	20.04.2016	2 321 272	Granted
IT	17.08.2009	09810900.2	20.04.2016	502016000073888	Granted
NL	17.08.2009	09810900.2	20.04.2016	2 321 272	Granted
SE	17.08.2009	09810900.2	20.04.2016	2 321 272	Granted
HK	17.08.2009	11107820.8	20.01.2017	1153726	Granted
IN	17.08.2009	267/MUMNP/2011	24.07.2018	299126	Granted
JP	17.08.2009	2011-524129	10.10.2014	5628173	Granted
KR	17.08.2009	10-2011-7004733	14.11.2016	10-1677519	Granted
US	17.08.2009	13/061,692	17.07.2012	8,222,447	Granted

Expiration dates No. 15:

TW 98128395: August 24, 2029

All other countries: August 17, 2029

No. 16: N 009 (Enantiomerically pure 3-fold substituted cyclohexyl compounds, intermediates for preparation of BC-3781)

Country	Filing Date	Application number	Grant date	Patent number	Status
EP	26.05.2010	10450093.9			Abandoned
WO	23.05.2011	PCT/AT2011/000236		WO 2011/146953	Terminated
TW	23.05.2011	100117949	01.09.2016	I547466	Granted
CN	23.05.2011	201180036299.0	03.08.2016	ZL201180036299.0	Granted
EP	23.05.2011	11721698.6	13.08.2014	2 576 531	Granted
AT	23.05.2011	11721698.6	13.08.2014	E 682166	Granted
BE	23.05.2011	11721698.6	13.08.2014	2 576 531	Granted
CH	23.05.2011	11721698.6	13.08.2014	2 576 531	Granted
DE	23.05.2011	11721698.6	13.08.2014	60 2011 009 074.7	Granted
DK	23.05.2011	11721698.6	13.08.2014	2 576 531	Granted
ES	23.05.2011	11721698.6	13.08.2014	2 576 531	Granted
FR	23.05.2011	11721698.6	13.08.2014	2 576 531	Granted
GB	23.05.2011	11721698.6	13.08.2014	2 576 531	Granted
IE	23.05.2011	11721698.6	13.08.2014	2 576 531	Granted
IT	23.05.2011	11721698.6	13.08.2014	502014902308294	Granted
NL	23.05.2011	11721698.6	13.08.2014	2 576 531	Granted
SE	23.05.2011	11721698.6	13.08.2014	2 576 531	Granted
IN	23.05.2011	2835/MUMNP/2012			Pending
JP	23.05.2011	2013-511475	14.10.2016	6023701	Granted
JP	23.05.2011	2016-154875			Abandoned
KR	23.05.2011	10-2012-7030732	30.05.2018	10-1864805	Granted
US	23.05.2011	13/699,585	24.03.2015	8,987,498	Granted
HK	23.05.2011	13110607.9	12.12.2014	HK1183298	Granted

Expiration dates No. 16:

All countries May 23, 2031

No. 17: N 010 (BC-3781 preparation process, BC-3781 crystalline free base and salts)

Country	Filing Date	Application number	Grant date	Patent number	Status
EP	26.05.2010	10450092.1			Abandoned
WO	23.05.2011	PCT/AT2011/000237			Terminated
TW	23.05.2011	100117950	01.06.2017	I585073	Granted
AU	23.05.2011	2011257938	06.10.2016	2011257938	Granted
BR	23.05.2011	BR112012029982-4			Pending
CA	23.05.2011	2,799,029			Pending
CN	23.05.2011	201180036554.1	02.03.2016	ZL201180036554.1	Granted
CN	23.05.2011	201510488095.0			Abandoned
DZ	23.05.2011	120789			Pending
EA	23.05.2011	201291370	31.05.2016	023273	Granted
EG	23.05.2011	PCT 1954/2012			Pending
EP	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
AT	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
BE	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
CH	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
DE	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
DK	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
ES	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
FR	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
GB	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
GR	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
HU	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
IE	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
IT	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
NL	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
PL	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
PT	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
SE	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
TR	23.05.2011	11724938.3	29.11.2017	2 576 505	Granted
ID	23.05.2011	W-00 2012 04885			Pending
IL	23.05.2011	222999	30.05.2016	222999	Granted
IN	23.05.2011	9451/DELNP/2012			Pending

Country	Filing Date	Application number	Grant date	Patent number	Status
JP	23.05.2011	2013-511476	11.11.2016	6038021	Granted
JP	23.05.2011	2016-175859			Pending
KR	23.05.2011	10-2012-7030731			Pending
LY	23.05.2011	4577/2012			Pending
MA	23.05.2011	35484	1.6.2013	34332	Granted
MX	23.05.2011	MX/A/2012/013645	17.04.2017	347176	Granted
MY	23.05.2011	PI2012700960	30.01.2018	MY-164666-A	Granted
NZ	23.05.2011	603804	01.07.2014	603804	Granted
PH	23.05.2011	1-2012-502321			Pending
SG	23.05.2011	201208033-9			Pending
SY	23.05.2011	2012120202			Pending
TN	23.05.2011	TN 2012/0506	04.06.2014	23093	Granted
UA	23.05.2011	a 2012 14910	27.04.2015	108378	Granted
US	23.05.2011	13/699,589	01.09.2015	9,120,727	Granted
ZA	23.05.2011	2012/08056	29.01.2014	2012/08056	Granted
HK	23.05.2011	13110606.0			Pending
EP	23.05.2011	17197350.6			Pending
HK	23.05.2011	18112372.3			Pending

Expiration dates No. 17:

All countries May 23, 2031


No. 18: N 011 (Amino(C₀₋₄)alkyl-hydroxy-(C_{4,5,7,8})cycloalkyl- and bicycloalkylsulfanyl)-acetyl Mutilins)

Country	Filing Date	Application number	Grant date	Patent number	Status
EP	09.09.2010	10450143.2			Abandoned
WO	11.08.2011	PCT/AT2011/000342			Terminated
TW	17.08.2011	100129397	01.11.2017	6125425	Granted
EP	11.08.2011	11751528.8	28.02.2018	2 614 049	Granted
DE	11.08.2011	11751528.8	28.02.2018	2 614 049	Granted
FR	11.08.2011	11751528.8	28.02.2018	2 614 049	Granted
GB	11.08.2011	11751528.8	28.02.2018	2 614 049	Granted
JP	11.08.2011	2013-527421	14.04.2017	6125425	Granted
US	11.08.2011	13/821,446	08.03.2016	9,278,920	Granted

Expiration dates No. 18:

Taiwan: August 17, 2031
 All other countries: August 11, 2031

No. 19: N 002 (Clavulanic acid derivatives)

Country	Filing Date	Application number	Grant date	Patent number	Status
AT	26.06.2008	A 1020/2008			Abandoned
AT	15.09.2009	A 1458/2009			Abandoned
WO	12.08.2010	PCT/AT2010/000297			Terminated
EP	12.08.2010	10747788.7	24.06.2015	2 477 993	Granted
DE	12.08.2010	10747788.7	24.06.2015	50 2010 009 739.2	Granted
FR	12.08.2010	10747788.7	24.06.2015	2 477 993	Granted
GB	12.08.2010	10747788.7	24.06.2015	2 477 993	Granted
US	12.08.2010	13/395,606	01.09.2015	9,120,808	Granted

Expiration dates No. 19

All countries August 12, 2030

No. 20: N 013 (C-14/C-12-epi substituted Pleuromutilins)

Country	Filing Date	Application number	Grant date	Patent number	Status
EP	22.01.2014	14152107.0			Abandoned
PCT	21.01.2015	PCT/EP2015/051159			Terminated
BR	21.01.2015	BR 11 2016 015542 4			Pending
CA	21.01.2015	2,935,415			Pending
CN	21.01.2015	201580005582.5			Pending
EP	21.01.2015	15701513.2			Pending
IL	21.01.2015	246454			Pending
IN	21.01.2015	201627023164			Pending
JP	21.01.2015	2016-547848			Pending
KR	21.01.2015	10-2016-7022050			Pending
MX	21.01.2015	MX/A/2016/008781			Pending
US	21.01.2015	15/111,390	11.07.2017	9,701,628	Granted
HK	21.01.2015	17100260.4			Pending

Expiration date No. 20:

January 21, 2035

No. 21: N 014 (Formulation BC3781)

Country	Filing Date	Application number	Grant date	Patent number	Status
US Provisional	17.06.2015	62/180,871			Abandoned
TW	15.06.2016	105118788			Pending
PCT	14.06.2016	PCT/EP2016/063609			Terminated
AU	14.06.2016	2016278774			Pending
BR	14.06.2016	BR112017026904-0			Pending
CA	14.06.2016	2,989,372			Pending
CN	14.06.2016	201680034551.7			Pending
EA	14.06.2016	201890075			Pending
EP	14.06.2016	16729258.0			Pending
HK	14.06.2016	18111844			Pending
IL	14.06.2016	256115			Pending
IN	14.06.2016	201717044310			Pending
JP	14.06.2016	2018-517478			Pending
KR	14.06.2016	10-2017-7037107			Pending
MX	14.06.2016	MX/a/2017/015812			Pending
PH	14.06.2016	1-2017-502319			Pending
UA	14.06.2016	a 2017 12491			Pending
US	14.06.2016	15/736,865			Pending
ZA	14.06.2016	2017/07998			Pending

Expiration date No. 21

Taiwan: June 15, 2036

All other countries: June 14, 2036

No. 22: N 016 (Pleuromutilin purification)

Country	Filing Date	Application number	Grant date	Patent number	Status
EP	10.02.2017	17155542.8			Abandoned
WO	09.02.2018	PCT/EP2018/053314			Pending
TW	06.02.2018	107104127		Not yet published	Pending

Expiration date No. 21

Taiwan: February 06, 2038
All other countries: February 09, 2038

Zavante

Intellectual Property

4.20(a)

1. U.S. Patent Appl. No. 14/497,022, entitled "Method for Improving Drug Treatments in Mammals," filed September 25, 2014, claiming priority to US Provisional Patent Appl. No. 61/882,436, filed September 25, 2013. Status: Granted; US 9,345,717, issued May 24, 2016. Owner: Zavante Therapeutics, Inc.
2. US Patent Appl. No. 15/136,704, entitled "Method for Improving Drug Treatments in Mammals," filed April 22, 2016, Continuation of US 9,345,717. Status: Granted; US10,086,006, issued October 2, 2018. Owner: Zavante Therapeutics, Inc.
3. US Patent Appl. No. 16/150,254, entitled "Method for Improving Drug Treatments in Mammals," filed October 2, 2018, Continuation of US 10,086,006. Status: Filed. Owner: Zavante Therapeutics, Inc.
4. PCT Patent Appl. No. PCT/US18/35035, entitled "Methods of Identifying Novel Dosing Regimens," filed May 30, 2018, claiming priority to US Provisional Patent Appl. No. 62/512,655, filed May 30, 2017, US Provisional Patent Appl. No. 62/567,599, filed October 3, 2017, and US Provisional Patent Appl. No. 62/582,880, filed November 7, 2017. Status: Pending. Owner: Zavante Therapeutics, Inc.
5. PCT Patent Appl. No. PCT/US18/13030, entitled "Methods for Identifying Novel Dosing Regimens," filed January 9, 2018 and published on July 12, 2018 as WO 2018/129560, claiming priority to US Provisional Patent Appl. No. 62/444,346, filed January 9, 2017. Status: Published. Owner: Zavante Therapeutics, Inc.
6. US Provisional Patent Appl. No. 61/882,436, filed September 25, 2013. Status: expired. Owner: Zavante Therapeutics, Inc.
7. US Provisional Patent Appl. No. 62/444,346, filed January 9, 2017. Status: expired. Owner: Zavante Therapeutics, Inc.
8. US Provisional Patent Appl. No. 62/567,599, filed October 3, 2017. Status: expired. Owner: Zavante Therapeutics, Inc.
9. US Provisional Patent Appl. No. 62/512,655, filed May 30, 2017. Status: expired. Owner: Zavante Therapeutics, Inc.
10. US Provisional Patent Appl. No. 62/582,880, filed November 7, 2017. Status: expired. Owner: Zavante Therapeutics, Inc.

EXHIBIT C

Trademarks

1. US Trademark Appl. No. 87/369,724 for CONTEPO, filed March 13, 2017. Status: Allowed, April 6, 2018. Classes: 05 Int.; Goods: 05 Int. Pharmaceuticals, namely, anti-infectives. Owner: Zavante Therapeutics, Inc.
2. US Trademark Appl. No. 87/369,716 for ZOLYD, filed March 13, 2017. Status: Abandoned, April 6, 2018. Classes: 05 Int.; Goods: 05 Int. Pharmaceuticals, namely, anti-infectives. Owner: Zavante Therapeutics, Inc.
3. US Service Mark Application No. 86/185,905, for ZAVANTE, filed February 6, 2014. Status: Registered, March 3, 2015, Registration No. 4,697,125. Class: 42 Int.; Goods: 42 Int., Providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Owner: Zavante Therapeutics, Inc.
4. US Service Mark Application No. 86/303,498, for ZAVANTE THERAPEUTICS, INC, filed June 8, 2014. Status: Registered, September 15, 2015, Registration No. 4,814,069. Class: 42 Int.; Goods: 42 Int., Providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Owner: Zavante Therapeutics, Inc.

EXHIBIT D

Mask Works

None.